Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | MC4R | P32245 | 5/20 | 0.40 |
| ▸ | MC5R | P33032 | 2/20 | 0.40 |
| ▸ | MC3R | P41968 | 2/20 | 0.40 |
| ▸ | HTR1F | P30939 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13713476 | 1.00 | HTR6 (0.41) | HTR6MC4RMC5RMC3RHTR1F | |
| Hydrochloric Acid SCHEMBL6612954 | 0.99 | HTR6 (0.40) | HTR6MC4RMC5RMC3RHTR1F | |
| Hydrochloric Acid SCHEMBL3123499 | 0.99 | HTR6 (0.40) | HTR6MC4RMC5RMC3RHTR1F | |
| SCHEMBL14540392 | 0.84 | MC4R (0.54) | MC4RMC5RMC3R | |
| SCHEMBL14540631 | 0.84 | MC4R (0.45) | MC4RMC5RMC3RHTR1FACACB | |
| SCHEMBL6867393 | 0.82 | MC4R (0.48) | MC4RMC5RMC3R | |
| SCHEMBL1697490 | 0.82 | HTR2C (0.46) | HTR1FHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1697486 | 0.82 | HTR2C (0.46) | HTR1FHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1697782 | 0.82 | HTR2C (0.46) | HTR1FHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14540632 | 0.77 | HTR6 (0.46) | HTR6HTR1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129413-B2 | Crystalline forms of MC4R agonist and process for synthesis | MERCK SHARP & DOHME CORP. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129413-B2 | Crystalline forms of MC4R agonist and process for synthesis | MERCK SHARP & DOHME CORP. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090233967-A1 | Crystalline forms of mc4r agonist and process for synthesis | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233967-A1 | Crystalline forms of mc4r agonist and process for synthesis | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| WO-2007002462-A2 | CRYSTALLINE FORMS OF MC4R AGONIST AND PROCESS FOR SYNTHESIS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233967-A1 | Crystalline forms of mc4r agonist and process for synthesis | MC4R, MC3R, MC2R | HTR6 300/4885MC4R 1/4885MC5R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.